# Advaxis, Inc. (ADXS)

Source: https://www.quantisnow.com/company/ADXS
Generated: 2026-11-13T21:58:08.750Z

- Ticker: ADXS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Major Pharmaceuticals
- IPO year: n/a
- Website: advaxis.com

## About

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

## Latest ADXS news and filings

- 2025-01-29 14:22 UTC [Leadership Update] [OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline](https://www.quantisnow.com/insight/os-therapies-agrees-to-acquire-all-listeria-monotygenes-based-immuno-oncology-programs-5861126)
- 2024-05-09 20:10 UTC [Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations](https://www.quantisnow.com/insight/ayala-pharmaceuticals-files-form-15-to-voluntarily-deregister-and-suspend-5477611)
- 2024-05-09 20:05 UTC [SEC Form 15-12G filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-advaxis-inc-5477468)
- 2024-04-26 21:03 UTC [SEC Form 10-K] [SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-10-ka-filed-by-advaxis-inc-amendment-5438352)
- 2024-04-19 11:50 UTC [SEC Form 8-K] [Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)](https://www.quantisnow.com/insight/advaxis-inc-filed-sec-form-8-k-financial-statements-and-exhibits-5420028)
- 2024-04-16 20:11 UTC [SEC Form 10-K] [SEC Form 10-K filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-advaxis-inc-5413338)
- 2024-04-15 20:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410973)
- 2024-04-15 20:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410972)
- 2024-04-15 20:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410970)
- 2024-04-15 20:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410969)
- 2024-04-15 20:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410965)
- 2024-04-15 20:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410960)
- 2024-04-15 20:31 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410955)
- 2024-04-15 20:31 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410946)
- 2024-04-15 20:30 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-advaxis-inc-5410943)
- 2024-04-03 21:01 UTC [SEC Form 8-K] [Advaxis, Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/advaxis-inc-filed-sec-form-8-k-leadership-update-5389693)
- 2024-04-01 20:31 UTC [SEC Form NT 10-K filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-advaxis-inc-5381255)
- 2024-03-29 21:06 UTC [SEC Form 8-K] [Advaxis, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/advaxis-inc-filed-sec-form-8-k-completion-of-acquisition-or-5378175)
- 2024-03-26 12:00 UTC [Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome](https://www.quantisnow.com/insight/ayala-pharmaceuticals-announces-completion-of-sale-of-al102-to-immunome-5367985)
- 2024-03-06 12:13 UTC [SEC Form 4] [SEC Form 4 filed by Israel Biotech Fund I, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-israel-biotech-fund-i-lp-5321127)
- 2024-03-05 13:16 UTC [SEC Form DEFM14C filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-defm14c-filed-by-advaxis-inc-5315923)
- 2024-02-23 21:30 UTC [SEC Form 8-K] [Advaxis, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/advaxis-inc-filed-sec-form-8-k-leadership-update-financial-statements-5288677)
- 2024-02-20 22:22 UTC [SEC Form PREM14C filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-prem14c-filed-by-advaxis-inc-5276740)
- 2024-02-20 13:15 UTC [Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors](https://www.quantisnow.com/insight/immunome-recognizes-ayala-pharmaceuticals-announced-completion-of-enrollment-in-phase-5273571)
- 2024-02-20 13:00 UTC [Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors](https://www.quantisnow.com/insight/ayala-pharmaceuticals-announces-completion-of-enrollment-in-phase-3-ringside-5273375)
- 2024-02-14 21:26 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-advaxis-inc-amendment-5263859)
- 2024-02-12 19:16 UTC [SEC Form 4] [Israel Biotech Fund I, L.P. exercised 27,847,159 shares at a strike of $0.40 and covered exercise/tax liability with 5,294,486 shares (SEC Form 4)](https://www.quantisnow.com/insight/israel-biotech-fund-i-lp-exercised-27847159-shares-at-a-5249725)
- 2024-02-12 16:58 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Advaxis, Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-advaxis-inc-amendment-5249308)
- 2024-02-12 13:27 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-advaxis-inc-amendment-5248493)
- 2024-02-09 22:15 UTC [SEC Form 8-K] [Advaxis, Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/advaxis-inc-filed-sec-form-8-k-unregistered-sales-of-equity-5247261)
- 2024-02-06 13:51 UTC [SEC Form 8-K] [SEC Form 8-K filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-advaxis-inc-5232500)
- 2024-02-06 13:00 UTC [Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals](https://www.quantisnow.com/insight/immunome-to-acquire-al102-a-phase-3-asset-for-the-5232236)
- 2024-02-06 13:00 UTC [Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals](https://www.quantisnow.com/insight/immunome-to-acquire-al102-a-phase-3-asset-for-the-5232186)
- 2024-01-03 21:18 UTC [SEC Form 8-K] [Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)](https://www.quantisnow.com/insight/advaxis-inc-filed-sec-form-8-k-financial-statements-and-exhibits-5165112)
- 2023-11-21 14:04 UTC [SEC Form 4] [SEC Form 4 filed by Israel Biotech Fund I, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-israel-biotech-fund-i-lp-5097871)
- 2023-11-21 14:00 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Advaxis, Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-advaxis-inc-amendment-5097851)
- 2023-11-20 14:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-advaxis-inc-5095130)
- 2023-11-16 19:12 UTC [Market Chatter] [Ladenburg Thalmann Downgrades Ayala Pharmaceuticals to Neutral](https://www.quantisnow.com/insight/ladenburg-thalmann-downgrades-ayala-pharmaceuticals-to-neutral-5090075)
- 2023-11-15 21:04 UTC [SEC Form NT 10-Q filed by Advaxis, Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-advaxis-inc-5087553)
- 2023-11-08 21:01 UTC [SEC Form 3] [New insider Cabilly Yuval claimed ownership of 1,298,639 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-cabilly-yuval-claimed-ownership-of-1298639-shares-sec-5070013)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ADXS
- Earnings history: https://www.quantisnow.com/earnings/ADXS
- Dividend history: https://www.quantisnow.com/dividends/ADXS
- Insider transactions: https://www.quantisnow.com/insiders/ADXS
- Options chain: https://www.quantisnow.com/options/ADXS
- SEC 8-K filings only: https://www.quantisnow.com/company/ADXS/8-k
- RSS and alerts for ADXS: https://www.quantisnow.com/docs/rss-feeds.md